Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP cenes from an H5N1 virus

Viral Immunology

Volumn 24, Issue 1, 2011, Pages 45-56

  Xu, Ke ^a   Ling, Zhi Yang ^b   Sun, Liang ^b   Xu, Ying ^b   Bian, Chao ^b   He, Yuan ^a   Lu, Wei ^a   Chen, Ze ^c   Sun, Bing ^a,b  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c Shanghai Institute of Biological Products   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; INTERLEUKIN 4; VIRUS ANTIBODY; VIRUS NUCLEOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; ELECTROPORATION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IN VIVO STUDY; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H9N2; MOUSE; NONHUMAN; PLASMID; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL PROLIFERATION; ELECTROPORATION; FEMALE; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA A VIRUS, H9N2 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; PLASMIDS; PROMOTER REGIONS, GENETIC; RNA-BINDING PROTEINS; SPLEEN; VACCINATION; VACCINES, DNA; VIRAL CORE PROTEINS;

INFLUENZA A VIRUS;

EID: 79951785009     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2010.0056     Document Type: Article

References (58)

1. Aihara H, and Miyazaki J: Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998;16:867-870. (Pubitemid 28405859)
2. Babiuk S, Baca-Estrada ME, Foldvari M, Storms M, Rabussay D, Widera G, and Babiuk LA: Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine 2002;20:3399-3408. (Pubitemid 35245823)
3. Bian C, Zhang X, Cai X, et al.: Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibody. Virology 2009;383:39-46.
4. Butt KM, Smith GJ, Chen H, et al.: Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003. J Clin Microbiol 2005;43:5760-5767.
5. Carragher DM, Kaminski DA, Moquin A, Hartson L, and Randall TD: A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 2008;181:4168-4176.
6. Cauthen A, Swayne D, Schultz-Cherry S, Perdue M, and Suarez D: Continued circulation in China of highly pathogenic avian influenza viruses encoding the hemagglutinin gene associated with the 1997 H5N1 outbreak in poultry and humans. J Virol 2000;74:6592-6599. (Pubitemid 30429828)
7. Centers for Disease Control and Prevention: Swine influenza (H1N1) infection in two children. MMWR Morb Mortal Wkly Rep 2009;58:400-402.
8. Chen J, Fang F, Li X, Chang H, and Chen Z: Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation. Vaccine 2005;23:4322-4328. (Pubitemid 40991237)
9. Chen MW, Cheng TJ, Huang Y, et al.: A consensus-hemagglutinin- based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci USA 2008;105:13538-13543.
10. Chen Z, Kadowaki S, Hagiwara Y, Yoshikawa T, Matsuo K, Kurata T, and Tamura S: Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine 2000;18:3214-3222. (Pubitemid 30408197)
11. Chen Z, Zhou P, Ho DD, Landau NR, and Marx PA: Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. J Virol 1997;71:2705-2714. (Pubitemid 27119907)
12. Claas ECJ: Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998;351:472-477.
13. Coles RM, Mueller SN, Heath WR, Carbone FR, and Brooks AG: Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1. J Immunol 2002;168:834-838. (Pubitemid 34049585)
14. Couch RB: An overview of serum antibody responses to influenza virus antigens. Dev Biol (Basel) 2003;115:25-30.
15. Davis HL: Intramuscular and intradermal injection of DNA vaccine in mice and primates methods in molecular medicine. DNA Vaccine Methods Protocols 29.
16. De Jong JC, Claas EC, Osterhaus AD, Webster RG, and Lim WL: A pandemic warning? Nature 1997;389:554.
17. Deng Y, Yewdell JW, Eisenlohr LC, and Bennink JR: MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. J Immunol 1997;158:1507-1515. (Pubitemid 127469502)
18. DiMenna LJ, and Ertl HC: Pandemic influenza vaccines. Curr Top Microbiol Immunol 2009;333:291-321.
19. Donnelly JJ, Friedman A, Martinez D, et al.: Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1995;1:583-587.
20. Donnelly JJ, Friedman A, Ulmer JB, and Liu MA: Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine 1997;15:865-868. (Pubitemid 27287977)
21. Donnelly JJ, Ulmer JB, Shiver JW, and Liu MA: DNA vaccines. Annu Rev Immunol 1997;15:617-648. (Pubitemid 27169294)
22. Epstein SL, Tumpey TM, Misplon JA, et al.: DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 2002;8:796-801.
23. Fraser C, Donnelly CA, Cauchemez S, et al.: Pandemic potential of a strain of influenza A (H1N1): early findings. Science 2009;324:1557-1561.
24. Fu TM, Ulmer JB, Caulfield MJ, et al.: Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med 1997;3:362-371. (Pubitemid 27353615)
25. Garten RJ, Davis CT, Russell CA, et al.: Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009;325:197-201.
26. Gerhard W, Mozdzanowska K, and Zharikova D: Prospects for universal influenza virus vaccine. Emerg Infect Dis 2006;12:569-574.
27. Jin H, Xiao C, Chen Z, et al.: Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARSCoV in mice. Biochem Biophys Res Commun 2005;328:979-986.
28. Johansson BE, and Kilbourne ED: Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition. Virology 1996;225:136-144. (Pubitemid 26390059)
29. Kodihalli S, Goto H, Kobasa DL, Krauss S, Kawaoka Y, and Webster RG: DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J Virol 1999;73:2094-2098. (Pubitemid 29098113)
30. Kodihalli S, Haynes JR, Robinson HL, and Webster RG: Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin. J Virol 1997;71:3391-3396. (Pubitemid 27172347)
31. Lin YP, Shaw M, Gregory V, et al.: Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc Natl Acad Sci USA 2000;97:9654-9658. (Pubitemid 30650831)
32. Nefkens I, Garcia JM, Ling CS, et al.: Hemagglutinin pseudotyped lentiviral particles: characterization of a new method for avian H5N1 influenza sero-diagnosis. J Clin Virol 2007;39:27-33. (Pubitemid 46575342)
33. Oehen S, and Brduscha-Riem K: Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J Immunol 1998;161:5338-5346. (Pubitemid 28519094)
34. Palese P, and Garcia-Sastre A: Influenza vaccines: present and future. J Clin Invest 2002;110:9-13. (Pubitemid 34743458)
35. Prokudina EN, and Semenova NP: Localization of the influenza virus nucleoprotein: cell-associated and extracellular non-virion forms. J Gen Virol 1991;72(Pt 7):1699-1702.
36. Riedel S: Crossing the species barrier: the threat of an avian influenza pandemic. Proc (Bayl Univ Med Cent) 2006;19:16-20.
37. Robinson HL, Hunt LA, and Webster RG: Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 1993;11:957-960. (Pubitemid 23218805)
38. Scheerlinck JP, Karlis J, Tjelle TE, Presidente PJ, Mathiesen I, and Newton SE: In vivo electroporation improves immune responses to DNA vaccination in sheep. Vaccine 2004;22:1820-1825.
39. Stitz L, Schmitz C, Binder D, Zinkernagel R, Paoletti E, and Becht H: Characterization and immunological properties of influenza A virus nucleoprotein (NP): cell-associated NP isolated from infected cells or viral NP expressed by vaccinia recombinant virus do not confer protection. J Gen Virol 1990;71(Pt 5):1169-1179. (Pubitemid 20174357)
40. Subbarao, K: Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998;279:393-396.
41. Subbarao K, Chen H, Swayne D, et al.: Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 2003;305:192-200. (Pubitemid 36062823)
42. Tollefsen S, Tjelle T, Schneider J, et al.: Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation. Vaccine 2002;20:3370-3378. (Pubitemid 35256081)
43. Tsai C, Caillet C, Hu H, et al.: Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase. Vaccine 2009;27:6777-6790.
44. Ulmer JB: Influenza DNA vaccines. Vaccine 2002;20(Suppl 2):S74-S76.
45. Ulmer JB, Deck RR, DeWitt CM, Friedman A, Donnelly JJ, and Liu MA: Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Vaccine 1994;12:1541-1544. (Pubitemid 24360571)
46. Ulmer JB, Donnelly JJ, Parker SE, et al.: Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-1749. (Pubitemid 23114660)
47. Ulmer JB, Fu TM, Deck RR, et al.: Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol 1998;72:5648-5653. (Pubitemid 28283349)
48. Virelizier JL, Allison AC, Oxford JS, and Schild GC: Early presence of ribonucleoprotein antigen on surface of influenza virus-infected cells. Nature 1977;266:52-54. (Pubitemid 8050009)
49. Wells DJ: Gene therapy progress and prospects: electroporation and other physical methods. Gene Ther 2004;11:1363-1369.
50. World Health Organization: Cumulative number of confirmed human cases of avian influenza A/(H5N1) Reported to WHO, 2010. http://www.who.int/csr/disease/ avian-influenza/country/en/.
51. World Health Organization: New influenza (H1N1) virus infections: global surveillance summary. Wkly Epidemiol Rec 2009;84.
52. World Health Organization: Recommended composition of influenza virus vaccines for use in the 2009-2010 influenza season, 2009. http://www.who.int/ csr/disease/influenza/200902-recommendation.pdf.
53. Widera G, Austin M, Rabussay D, et al.: Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000;164:4635-4640. (Pubitemid 30238062)
54. Wong SS, and Yuen KY: Avian influenza virus infections in humans. Chest 2006;129:156-168. (Pubitemid 43265257)
55. Wood JM, and Robertson JS: From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol 2004;2:842-847. (Pubitemid 39317465)
56. Yang ZY, Wei CJ, Kong WP, Wu L, Xu L, Smith DF, and Nabel GJ: Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science 2007;317:825-828. (Pubitemid 47257924)
57. Yewdell JW, Bennink JR, Smith GL, and Moss B: Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1985;82:1785-1789. (Pubitemid 15085262)
58. Zheng L, Wang F, Yang Z, Chen J, Chang H, and Chen Z: A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice. BMC Infect Dis 2009;9:17.